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Summary
Objective: To investigate the relationship between baseline radiographic severity of knee osteoarthritis (OA) and the importance of long-term
joint space narrowing.
Design: Sub-analysis from a three-year randomized, placebo-controlled, prospective study, of 212 patients with knee OA, recruited in an
osteoarthritic outpatient clinic and having been part of a study evaluating the effect of glucosamine sulfate on symptom and structure
modification in knee OA.
Material and Methods: Measurements of mean joint space width (JSW), assessed by a computer-assisted method, were performed at
baseline and after 3 years, on weightbearing anteroposterior knee radiographs.
Results: In the placebo group, baseline JSW was significantly and negatively correlated with the joint space narrowing observed after 3 years
(r= −0.34, P=0.003). In the lowest quartile of baseline mean JSW (<4.5 mm), the JSW increased after 3 years by (mean (S.D.)) 3.8% (23.8)
in the placebo group and 6.2% (17.5) in the glucosamine sulfate group. The difference between the two groups in these patients with the
most severe OA at baseline was not statistically significant (P=0.70). In the highest quartile of baseline mean JSW (>6.2 mm), a joint space
narrowing of 14.9% (17.9) occurred in the placebo group after 3 years while patients from the glucosamine sulfate group only experienced
a narrowing of 6.0% (15.1). Patients with the most severe OA at baseline had a RR of 0.42 (0.17–1.01) to experience a 0.5 mm joint space
narrowing over 3 years, compared to those with the less affected joint. In patients with mild OA, i.e. in the highest quartile of baseline mean
JSW, glucosamine sulfate use was associated with a trend (P=0.10) towards a significant reduction in joint space narrowing.
Conclusion: These results suggest that patients with the less severe radiographic knee OA will experience, over 3 years, the most dramatic
disease progression in terms of joint space narrowing. Such patients may be particularly responsive to structure-modifying drugs. © 2003
OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Osteoarthritis (OA) is a major cause of pain and physical
disability in the elderly1. Since the elderly population is
more in search of a pain-free active life, the management
of knee OA, the location responsible for the most important
pain and disability, has become a major social and
economic issue in health management2. It is now widely
recognized that the rate of structural progression of OA
may significantly differ from a patient to another3–6. How-
ever, since the determinants of OA progression are not yet
fully understood7, it remains rather difficult to predict which
individual patients will deteriorate, experience the most1severe functional impairment and eventually require joint
replacement surgery2. Several studies have aimed at the
identification of predictive factors for rapid OA progression.
Most of the studies focused on the predictive value of
clinical factors to identify patients with the most severe
osteoarthritis progression6,8,9, but relatively few studies
weighted the value of current radiological severity on future
structural outcomes. The aim of the present study was
to investigate whether radiographic knee OA severity,
assessed by a precise joint space width (JSW) measure-
ment, was correlated to the future structural progression of
the disease, over a three-year period of follow-up.Patients and methods
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The study population, more extensively described in a
previous publication10, was constituted by 212 subjects,
2 O. Bruyere et al.: Relationship between radiographic OA status and progressionMETHODSX-rays acquisition
Standard radiographs were taken for each knee at
baseline and after 3 years. The patients stood with their
knees fully extended and the posterior aspect of the knees
in contact with a vertical cassette in a cassette holder. The
lower limbs were internally rotated until the patella was
centralized over the lower end of the femur. The feet were
parallel and positioned a small distance apart. Foot maps
were used for repositioning the patient at the time of
subsequent X-rays. The X-ray beam was centered on the
joint space and parallel to the tibial plateau. Fluoroscopy
was used to correct lower limb positioning and X-ray beam
alignment. The focus film distance was 110 cm.JSW measurement
Radiographs were digitized and image analysis was
performed according to a validated technique12, which
located the proximal and distal joint margins excluding
outlier points and calculated the mean joint space width
(JSW) of the medial compartment of the tibiofemoral joint.
The mean (S.D.) short-term and long-term coefficient of
variation of this system for reproducing measurements was
1.82% (1.29) and 1.62% (1.31), respectively10.Statistical analysis
Quantitative variables were expressed as mean±S.D. and
qualitative variables were reported as absolute or relative
frequencies. The association between baseline JSW and
3-year joint space narrowing was assessed by the Pearsoncoefficient of correlation, in the placebo and the glu-
cosamine sufate groups separately, to avoid any interaction
of the treatment effect. We also performed, in the placebo
group, a multivariate analysis in which the dependant
variable was the 3-year changes in JSW and the indepen-
dent variables include the patient’s characteristics (age,
BMI), the symptoms (pain, function and stiffness subscales
of the WOMAC) and baseline JSW. In order to investigate
the real progression of the disease, the analysis has been
performed only in the 3-year completers and not in
intention-to-treat. In order to evaluate whether the baseline
levels of JSW affect the structural response to glucosamine
sulfate, we compared the 3-year joint space narrowing in
the placebo and in the glucosamine sulfate group, in the
highest and the lowest quartiles of baseline JSW. The
differences between quartiles were assessed by ANOVA. In
each quartile we looked at the number of patients who
experienced a relevant joint space narrowing over a 3-year
period. Based on the literature, any loss above 0.5 mm was
considered as relevant13. We eventually calculated the
relative risk [RR (95% CI)] of having a joint space narrowing
over 3 years greater than 0.5 mm in the lowest as com-
pared to the highest quartile. This arbitrary cut-off of
0.5 mm in JSW was based on the paper by Lequesne et
al.13 in which a difference of 0.5 mm in joint space narrow-
ing between an active drug and a comparator, was sug-
gested to be a relevant primary endpoint in a study looking
at disease modifying drugs in OA. The results were con-
sidered significant at the 5% level (P<0.05). Statistical
calculations were carried out with the SAS software (SAS
Institute, Cary, NC, U.S.A.).Table I
Baseline characteristics of the patients in the placebo and glucosamine sulfate group stratified into quartiles of
baseline joint space width (JSW)
Placebo Glucosamine sulfate
Quartile 1*
(N=23)
Mean±S.D.
Frequencies
(%)
Quartile 4†
(N=26)
Mean±S.D.
Frequencies
(%) P-value
Quartile 1*
(N=29)
Mean±S.D.
Frequencies
(%)
Quartile 4†
(N=27)
Mean±S.D.
Frequencies
(%) P-value
Sex
Men 17 (74) 21 (81) 0.56 21 (72) 19 (70) 0.87
Women 5 (26) 5 (19) 8 (28) 8 (30)
Age (years) 67.6±7.8 65.2±6.5 0.26 67.1±8.2 67.5±7.4 0.86
Height (cm) 160.5±7.2 160.0±6.9 0.78 160.3±9.5 162.4±10.9 0.44
Weight (kg) 73.0±9.5 69.0±8.6 0.13 71.5±10.3 71.3±11.5 0.94
Body mass index (kg/m2) 28.2±2.3 26.9±2.5 0.06 27.7±2.3 26.9±2.7 0.22
*Baseline JSW <4.5 mm.
†Baseline JSW >6.2 mm.Results
No statistically significant differences for age (P=0.31),
BMI (P=0.46) or sex (P=0.64) were observed between the
patients who completed the 3-year study and those who
prematurely discontinued. We also did not find any signifi-
cant difference between the baseline demographics of the
patients from the highest and the lowest quartiles of base-
line JSW (Table I), most likely because of the small size of
our sample. We found no statistically significant differences
between the baseline characteristics of the glucosamine
sulfate group and the placebo group, nor in the lowest
quartile neither the highest quartile of OA severity. From thefrom both genders aged from at least 50 years, with primary
knee OA. They were issued from a double-blind, placebo-
controlled study evaluating, over a period of 3 years, the
symptomatic and structural effects of glucosamine sulfate
in OA. Knee OA was diagnosed according to the clinical
and radiological criteria of the American College of
Rheumatology11. 106 patients were randomized to both the
placebo and the treated groups from whom 71 and 68
completed the 3-year study, respectively.
Osteoarthritis and Cartilage, Vol. 11, No. 1 3212 patients enrolled in the study, 139 completed the
3-year study: 71 in the placebo group (14 and 19 in quartile
1 and 4, respectively) and 68 in the glucosamine sulfate
group (16 and 19 in quartile 1 and 4, respectively).
In the placebo group, baseline JSW was significantly and
negatively correlated with the 3-year joint space narrowing
(r= −0.34, P=0.003). In the placebo group (N=71), a
multivariate analysis including demographics (age, BMI)
and symptoms (pain, function and stiffness of the
WOMAC), showed baseline JSW to be the only variable
borderline significant (P=0.07) for the prediction of the
structural progression observed after 3 years (Table II).
In the lowest quartile of baseline JSW (<4.5 mm), mean
(S.D.) JSW increased after 3 years by 3.8% (23.8) while a
joint space narrowing of 14.9% (17.9) was observed in
the highest quartile (baseline mean JSW >6.2 mm). The
joint space variations observed in the two quartile are
statistically different (P=0.01) (Fig. 1). The increase in JSW
reached 0.13 (0.81) mm in the lowest quartile and for a
decrease of 1.05 (1.28) mm in the highest quartile. In the
lowest quartile, 4/14 patients (28.6%) experienced a joint
space narrowing greater than 0.5 mm over 3 years com-
pared to 13/19 (68.4%) in the highest quartile. The relative
risk of having a joint space loss over 0.5 mm, in patients
with the less severe OA at baseline (highest quartile of
JSW) was 2.39 (95% CI: 0.99–5.79) compared to those
from the lowest quartile of JSW at baseline.
In the glucosamine sulfate-treated patients, baseline
JSW was significantly and negatively correlated with the
3-year joint space narrowing (r= −0.28, P=0.019). JSW
increased by 6.2% (17.5) over 3 years in the lowest quartile
(baseline JSW <4.5 mm), i.e. almost twice the value
observed in the placebo group and decreased by only 6.0%
(15.1) in the highest quartile (baseline JSW >6.2 mm), i.e.more than 50% less than in the placebo group (Fig. 1). In
absolute value, the increase in JSW was 0.22 (0.66) mm
in the lowest quartile and the decrease of 0.45 (1.04) mm in
the highest quartile. In the lowest quartile, 1/16 patients
(6.3%) experienced a joint space narrowing greater than
0.5 mm over 3 years compared to 9/19 (47.4%) in the
highest quartile. In the most severely affected patients, the
3-year joint space narrowing observed in the placebo group
was not statistically different from the one observed in the
glucosamine sulfate-treated group (P=0.70). However, in
patients with the lowest initial degree of OA, i.e. in the
highest quartile of baseline mean JSW, glucosamine sul-
fate use was linked to a trend (P=0.10) towards a reduction
in joint space narrowing (Fig. 1). The number of patients
needed to treat (NNT) with glucosamine sulfate, to prevent
one joint space narrowing of at least 0.5 mm over 3 years is
4.48 in the lowest quartile and 4.75 in the highest quartile.
Compared to patients treated with placebo, patients on
glucosamine sulfate had a RR of experiencing a joint space
narrowing greater than 0.5 mm over 3 years of 0.69 (95%
CI: 0.39–1.22) in the lowest quartile of baseline JSW and of
0.22 (95% CI: 0.03–1.73) in the highest quartile.Table II
Multivariate analysis results for the prediction of 3-year changes in
JSW (N=71)
Variable Parameter
estimate
S.E. P-value
Age −0.003 0.003 0.36
BMI 0.012 0.009 0.18
JSW at baseline −0.048 0.026 0.07
Pain subscale of the WOMAC −0.00008 0.0003 0.81
Stiffness subscale of the WOMAC 0.0005 0.0005 0.29
Function subscale of the WOMAC 0.00006 0.00009 0.51Fig. 1. 3-year changes in JSW stratified for quartiles of baseline
JSW in the placebo and the glucosamine sulfate group.Discussion
It is now widely recognized that the rate of clinical and
radiological progression of OA may significantly differ
between patients2. In order to identify patients who will
suffer from a rapid progression, several studies aimed at
selecting the most predictive risk factors for the progression
of OA. Some studies were mainly focused on demo-
graphic characteristics and symptoms changes. In the
Bristol ‘OA500’ study3, the 3-year clinical progression of
OA, defined as a self-reported worsening of the overall
condition, was more severe in women, older patients and
those with severe pain at entry.
Other studies also investigated which clinical or demo-
graphical baseline features were related to the structural
progression of OA. In 508 patients aged between 50 and
75 years9, the parameters predictive of the one-year radio-
logical progression of hip OA (i.e. a change of a least
0.6 mm in JSW) were a Lequesne’s functional index >10
[OR: 2.66 (95% CI: 1.46–4.83)], age at entry >65 years [OR
1.90 (95% CI: 1.18–3.08)] and to be a women [OR, 2.51
(95% CI: 1.49–4.23)]. In a 5-year study, 354 men and
women aged >55 years were followed for their knee OA8.
Structural progression, assessed by the changes in the
Kellgren and Lawrence scale14, was significantly increased
among subjects with higher baseline body mass index [OR:
18.3 (95% CI: 5.1–65.1)], previous knee injury [OR: 4.8
(95% CI: 1.0–24.1)] and history of regular sports participa-
tion [OR: 3.2 (95% CI: 1.1–9.1)]. Knee pain at baseline [OR
2.4 (95% CI: 0.7–8.0] and Heberden’s nodes [OR 2.0 (95%
CI 0.7–5.7)] were weakly associated with progression.
Another study, with 12 years of follow-up of patients with
knee OA6, reported the same prognostic factors for a
decrease in JSW between two radiographs: higher body
mass index, older age, presence of Heberden’s nodes but
also other factors like clinical diagnosis of generalized
osteoarthritis or previous bow legs or knock knees.
Few studies investigated whether baseline radiographic
severity of OA was related to radiological long-term pro-
gression. When considering the predictors of whole body
OA progression in a follow-up of 1 to 9 years of a cohort of
elderly women15, using the grading method of Kellgren and
Lawrence on 10 joint groups, an increased length of
4 O. Bruyere et al.: Relationship between radiographic OA status and progressionfollow-up and a lower baseline OA score were associated
with greater OA progression. In another trial5, 63 subjects
were followed for a mean of 11 years and knee radiographs
were read and scored with the Kellgren and Lawrence
scale. At baseline, 35.5% of knees were radiologically
normal while grade 1 to 4 corresponded respectively to
17.5%, 24.5%, 9% and 1.6% of the population. During this
follow-up period, only one-third of the patients worsened,
maybe because of the relatively poor sensitivity to changes
of the OA grading score16. Nevertheless, the proportion of
knees deteriorating of at least one Kellgren and Lawrence
grade was 48% in knee scored 0 at baseline, 45% for knee
scored 1, 38% for knee scored 2 and 16% for knee scored
3. Theses results are consistent with the present study
where patients with the less affected knee OA, assessed
by the medial femoro-tibial JSW measurement, with a
computer-assisted method, do experience, over 3 years,
the most severe structural progression. Our results
obtained from a longitudinal study investigating the exact
weight of radiological features on structural outcomes, with
changes in JSW assessed with a precise and sensitive
method, confirm therefore data obtained in previous obser-
vational studies. However, in hip OA, discrepant results
were reported, with progression being significantly
increased, after one year of follow-up, if baseline radiologi-
cal joint space width was <2 mm9. While the explanation
for this discrepancy remains unclear, this might re-
emphasize the different pathogenesis processes under-
lying the progression of the disease at different locations. In
our study, data were pooled for men and women. However,
some studies suggested that the age-related morphology
of knee joint cartilage17 or the onset of knee OA18 could
differ between genders. Similarly, the rate of progression
could have been different between the 3-year completers
and the premature withdrawals with a significant impact on
the overall results. However, the baseline characteristics of
the two populations were not significantly different and only
eight patients (five in the placebo group and three in the
glucosamine sulfate group) withdrew from the study
because of a lack in efficacy.
Our results suggest that OA should be diagnosed at the
early stages of the disease, in order to initiate therapy when
the potential for progression of the disease is high and
when structural treatments appear to be the most effective.
As a consequence, more accurate techniques for the early
diagnosis of the disease should be validated. Magnetic
resonance imaging, while potentially more accurate and
precise than conventional X-rays, still suffers from a clear
lack of accessibility17. Other imaging techniques, like com-
puter tomography, ultrasonography and bone scanning
have not been fully validated for this specific purpose19.
Biochemical markers of bone, cartilage and synovium are
actually studied and could be potentially useful20. Further-
more, patients with mild to moderate knee OA should be
treated not only for their symptoms but also to prevent
cartilage loss. The risk in treating such patients only for
symptoms (pure analgesics, NSAIDs, etc.) is that structural
alteration may progress rapidly. In our study, we assessed
the effect of glucosamine sulfate, a structure modifying OA
drug, on cartilage loss in patients with knee OA. The
compound was effective in reducing joint space narrowing
and symptoms over a 3-year period10, as recently con-
firmed in another trial21. In the present secondary analysis,
albeit not statistically significant between the two groups,
mainly because of the low statistical power due to the low
number of patients in each quartile of JSW (there were 212
patients in the initial study10), glucosamine was found toreduce joint space loss by 50% compared to the placebo,
with a strong trend towards a statistical significance
(P=0.1), in patients with the less affected joints. Con-
versely, our results show that patients with the most severe
cartilage alteration at baseline did not experience an appar-
ent disease progression over 3 years in terms of joint space
narrowing. This may represent a burnout effect after reach-
ing a certain level of OA, as previously reported in a
longitudinal study of the hand22. An hypothesis for a
stabilization or even an increase in JSW over 3 years could
involve: the repair of chondral defects, occurring early after
the cartilage loss, and characterized by chondrocytes
clustering (mitosis and/or migration) cartilage hypertrophy,
an increase in glycosaminoglycans, fibronectin and water
content in the cartilage as a result of an increased
glycosaminoglycan and collagen synthesis by chondro-
cytes23. At the more severe structural stage of OA, with no
detectable progression over time, glucosamine sulfate was
not able to induce a statistically significant difference com-
pared with placebo, notwithstanding the magnitude of the
increase in JSW was twice higher than in the placebo
group, i.e. an observation that would deserve further inves-
tigations in an appropriately powered study. Glucosamine
was reported to act, at least partly, by being a precursor of
proteoglycans synthesis24. Proteoglycans are instrumental
in helping cartilage to capture water and in promoting
formation of an elastic layer, factors which may improve the
functional characteristics of cartilage25. In patients with less
damage in their cartilage structure, cartilage could thus be
more responsive to the effects of glucosamine sulfate.
Conversely, in patients with a more advanced structural
damage at baseline, radiographic severity was associated
to a high degree of pain26,27 and physical impairment28
resulting in a decreased health-related quality of life. It can
thus be reasonably assumed that short or mid term out-
comes for these patients with severe knee OA are likely to
include joint prosthesis replacement. Severe radiological
joint space narrowing at diagnosis was previously
reported29 to be a predictor of the need for total hip
replacement in patients with OA of the hip. In order to delay
the joint replacement, patients with a high severity of OA
could then be treated preferentially with the aim to reduce
symptoms. Nevertheless, it could be interesting to investi-
gate whether glucosamine sulfate or another structure-
modifying OA drug is able to delay the need for joint
replacement as compared to purely symptomatic medi-
cations. Our results allow also reconsideration of the
inclusion and exclusion criteria used for trials assessing the
efficacy of disease modifying drugs in OA. The structure-
modifying effect of a drug should be more easily demon-
strated in a population with a high risk of progression over
time, hence excluding OA patients with severe radiologic
lesions who are less likely to experience severe progres-
sion. Moreover, when including patients with mild to mod-
erate OA, the difference between the treated and placebo
groups could be investigated at a lower cost because of a
significant decrease either in the number of patients
included or in the duration of the trials.
From this sub-analysis of a 3-year randomized, placebo-
controlled, prospective study evaluating the effects of glu-
cosamine sulfate, our results suggest that patients with the
less severe structural knee OA at baseline will experience,
over 3 years, the most severe radiographical progression.
Such patients may be particularly responsive to structure-
modifying drugs.
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